“ASSESSMENT OF BLOOD MARKERS AFTER RADIONUCLIDE THERAPY FOR OSTEOGENIC METASTASIS OF KIDNEY AND PROSTATE CANCER ”. World Bulletin of Public Health 12 (July 11, 2022): 66–69. Accessed February 3, 2026. https://scholarexpress.net/index.php/wbph/article/view/1135.